ESC 365 - Role of serum biomarkers for monitoring disease progression in the cardio-specific alpha-galactosidase A genotype N215S

ESC Premium Access

Role of serum biomarkers for monitoring disease progression in the cardio-specific alpha-galactosidase A genotype N215S

Session: Cardiomyopathy in Fabry disease

Topic: Cardiomyopathies

Speaker: Doctor D. Oder (Würzburg, DE)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Daniel Oder

University Hospital Würzburg, Würzburg (Germany)

0 follower

6 more presentations in this session

Comprehensive cardiovascular magnetic resonance assessment of anderson-fabry cardiomyopathy- natural history and assessment of treatment effect

Speaker: Doctor A. Reid (Manchester, GB)

Treatment of Fabry disease with a new oral drug: Initial real-world single-center experience

Speaker: Mr J. Muentze (Wuerzburg, DE)

Prompt initiation of agalsidase alfa therapy is associated with improved cardiovascular outcomes in the Fabry Outcome Survey

Speaker: Professor A. Linhart (Prague, CZ)

Efficacy of enzyme replacement therapy in Fabry disease with advanced organ involvement

Speaker: Doctor P. Nordbeck (Wuerzburg, DE)

Long-term benefit of enzyme replacement therapy on cardiac manifestation in Japanese Fabry disease

Speaker: Doctor I. Anan (Tokyo, JP)

Access the full session

Cardiomyopathy in Fabry disease

Speakers: Doctor D. Oder, Doctor A. Reid, Mr J. Muentze, Professor A. Linhart, Doctor P. Nordbeck...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources